Investigating Meningococcal Vaccines in Adults

You may not qualify if:

• Have any known or suspected impairment or alteration of immune function, resulting from, for example:
• Congenital or acquired immunodeficiency (including IgA deficiency)
• Human Immunodeficiency Virus (HIV) infection or symptoms/signs suggestive of an HIV-associated condition
• Autoimmune disease
• Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 12 months or long-term systemic corticosteroid therapy.
• Chronic illness that could interfere with immunological function or donation of the required volumes of blood (e.g. cardiac or renal disease, diabetes, or auto-immune disorders).
• Receipt of a live vaccine within 4 weeks prior to vaccination or a killed vaccine within 7 days prior to vaccination.
• History of group B meningococcal vaccination
• Have received a dose of a meningococcal groups A, C, W, Y conjugate vaccine within 30 days of enrolment or wish to receive a dose of this vaccine during the study period.
• Plan to receive any vaccine other than the study vaccine within 4 weeks following vaccination.
• History of severe allergic reaction after vaccination or known hypersensitivity to any vaccine component
• History of meningococcal disease
• Receipt of blood, blood products, or plasma derivatives within the past 3 months.
• Recent significant blood donation (e.g., to the National Blood Service) within 8 weeks of enrolment, or plans to donate blood during the study period.
• Thrombocytopenia or any bleeding disorder.
• +4 more criteria